Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Finch is a microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. Its lead candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection (CDI). In June 2020, the company reported positive topline data from its first pivotal trial in recurrent CDI, and plans to initiate a Phase 3 trial as its second and final pivotal trial in mid-2021.
The Somerville, MA-based company was founded in 2014 and booked $8 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol FNCH. Finch Therapeutics Group filed confidentially on December 28, 2020. BofA Securities, Jefferies and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
